Other conditions related to polyarteritis nodosa

M13_POYARTOTH

Polyarteritis Nodosa: ['A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative. [ NCI ]']

Suggest a new description

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — M30.8 Hospital discharge: ICD-9 — 4460C Cause of death: ICD-10 — M30.8 Cause of death: ICD-9 — 4460C 2 out of 7 registries used, show all original rules.	87
4. Check minimum number of events None	87
5. Include endpoints None	87
6. Filter based on genotype QC (FinnGen only)	87

Control definitions (FinnGen only)

Control exclude: M13_SYSTCONNECT

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: M30
Name in latin: Aliae condiciones polyarteritidi nodosae cognatae

NAME	M13_POYARTOTH
CONTROL_EXCLUDE	M13_SYSTCONNECT
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	M308
HD_ICD_9	4460C
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	M308
COD_ICD_9	4460C
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Other conditions related to polyarteritis nodosa based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	581	336	240
Only index persons	484	287	197
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	64.23	64.19	64.15
Only index persons	62.10	63.01	60.78

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	87	54	33
Unadjusted period prevalence (%)	0.02	0.02	0.01
Median age at first event (years)	57.75	54.01	63.87

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
82: Matched controls
821

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

M30.8

ICD-10 Finland

Other conditions related to polyarteritis nodosa

+∞

112.5

H02AB06

ATC

prednisolone; systemic

21.3

24.9

274

L04AX01

ATC

azathioprine; systemic

33.8

20.2

M30.0

ICD-10 Finland

Polyarteritis nodosa

+∞

18.4

202

Kela drug reimbursment

Connective tissue diseases, rheumatoid arthritis and comparable disease

12.1

16.1

A12AX

ATC

Calcium, combinations with vitamin D and/or other drugs

6.8

14.9

180

NK4XE

NOMESCO Finland

Joint ultrasound examination not elsewhere classified

12.5

10.1

L04AX03

ATC

methotrexate; systemic (immunosuppressants)

7.8

10.1

GD1AA

NOMESCO Finland

Thorax X-ray examination

4.6

9.9

241

M05BA04

ATC

alendronic acid; oral

8.7

9.6

NK6QA

NOMESCO Finland

Measurement of bone density from tow or more locations with X-ray

12.9

9.3

H02AB07

ATC

prednisone; oral

6.0

8.6

M31.7

ICD-10 Finland

Microscopic polyangiitis

+∞

8.5

M31.9

ICD-10 Finland

Necrotizing vasculopathy, unspecified

+∞

8.5

M30.1

ICD-10 Finland

Polyarteritis with lung involvement [Churg-Strauss]

+∞

8.5

PAW37

NOMESCO Finland

Biopsy of temporal artery

+∞

8.5

J18.9

ICD-10 Finland

Pneumonia, unspecified

4.5

8.4

116

H02AB09

ATC

hydrocortisone; systemic

25.1

8.3

A49.9

ICD-10 Finland

Bacterial infection, unspecified

6.1

7.3

N03AX16

ATC

pregabalin; oral

4.0

7.3

123

TNX10

NOMESCO Finland

Arthrocentesis, unspecified region, unspecified region

8.1

6.9

GD1DD

NOMESCO Finland

High resolution CT examination of lungs

10.1

6.9

TAB00

NOMESCO Finland

Lumbar puncture

10.6

6.5

UDH02

NOMESCO Finland

Rhinopharyngoscopy

7.4

6.5

R50.9

ICD-10 Finland

Fever, unspecified

5.1

6.5

ZX120

NOMESCO Finland

Intravenous

5.1

6.5

D69.0

ICD-10 Finland

Allergic purpura

29.2

6.4

E27.3

ICD-10 Finland

Drug-induced adrenocortical insufficiency

+∞

6.3

L95.9

ICD-10 Finland

Vasculitis limited to skin, unspecified

+∞

6.3

M35.0

ICD-10 Finland

Sicca syndrome [Sjögren]

+∞

6.3

DM1AA

NOMESCO Finland

Paranasal sinuses X-ray examination without contrast

16.6

6.1

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3003284) Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence

30.66

44.58

4.0

1.5

titre

242.9

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

23.29

30.10

8.9

1.3

iu/ml

14.0

—

(3037522) Nuclear Ab [Titer] in Serum

9.01

22.71

2.4

1.3

titre

651.4

480.0

0.40

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

15.95

19.15

3.6

1.4

—

(42870588) Differential panel, method unspecified - Blood

214

6.13

15.51

14.5

4.5

—

(3002179) Metamyelocytes/100 leukocytes in Blood

6.77

14.26

6.8

2.6

0.6

0.5

—

(3025159) Blasts/100 leukocytes in Blood

6.64

14.00

7.7

2.9

0.0

—

(3021440) Promyelocytes/100 leukocytes in Blood

6.64

14.00

7.9

3.0

0.0

0.1

0.07

(3017181) Myelocytes/100 leukocytes in Blood

6.30

13.56

7.7

3.0

0.8

0.5

0.36

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

24.74

13.11

6.6

1.1

—

(3023368) Bacteria identified in Blood by Culture

177

4.39

10.71

7.3

4.8

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

12.45

10.37

1.3

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

231

4.31

10.29

7.0

2.9

—

(1616796) Gas panel - Central venous blood

10.55

10.11

2.8

3.8

—

(3027450) Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum

11.30

9.74

2.2

1.5

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

11.30

9.74

1.8

1.2

—

(3004588) Protein electrophoresis panel - Serum or Plasma

6.04

9.07

1.8

1.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

4.38

8.71

2.2

1.7

—

(40760892) CBC W Ordered Manual Differential panel - Blood

168

3.72

8.31

13.4

5.8

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

333

4.00

8.29

8.7

8.4

mmol/l

1.2

0.45

287

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

10.14

8.25

1.2

2.0

—

(3018095) Leukocytes [#/volume] in Urine

239

3.57

7.89

7.9

3.3

e6/l

13.8

45.7

1.70

177

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

9.29

7.74

1.2

1.9

—

(3032080) INR in Blood by Coagulation assay

271

3.45

7.36

12.3

8.3

inr

1.2

0.16

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

115

3.63

7.15

2.3

1.8

—

(3036481) Cortisol [Moles/volume] in Serum or Plasma

3.99

6.54

3.3

1.9

nmol/l

240.8

403.6

3.13

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

270

3.15

6.42

8.3

3.6

ng/l

27.2

47.1

0.67

183

(40762485) Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay

19.81

6.41

1.8

1.2

—

(3007164) IgA [Mass/volume] in Serum or Plasma

129

3.34

6.40

2.1

1.3

g/l

2.6

2.4

0.20

(3002582) Erythrocytes [#/volume] in Urine

209

3.09

6.25

7.1

2.8

e6/l

14.6

31.6

1.17

168

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

132

3.25

6.13

1.7

1.6

mg/l

1.3

1.1

0.21

109

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

12.35

5.96

1.2

2.2

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

6.52

5.77

1.5

1.6

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

6.52

5.77

1.5

1.6

—

(3037467) Urinalysis macro (dipstick) panel - Urine

474

3.71

5.71

9.8

4.1

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

3.53

5.32

1.4

1.5

—

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

4.04

5.18

6.3

5.2

mmol/l

1.2

0.20

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

9.87

4.91

1.2

2.0

—

(3042631) Mycobacterium sp identified in Specimen

12.41

4.89

1.8

7.9

—

(3030467) Casts [#/volume] in Urine by Automated count

185

2.74

4.86

7.6

2.7

e6/l

0.1

0.4

1.71

146

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

3.11

4.81

1.4

1.7

—

(36304419) Bacteria [Presence] in Urine

180

2.71

4.70

7.1

2.7

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

416

2.86

4.69

5.9

6.0

mmol/l

6.9

6.7

0.17

389

(3022313) Gas panel - Capillary blood

5.25

4.66

2.0

3.2

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

4.70

4.50

1.9

2.6

—

(3026493) Urate [Moles/volume] in Serum or Plasma

177

2.64

4.43

3.3

2.7

umol/l

342.9

7295.0

1.06

145

(3035350) Ketones [Presence] in Urine by Test strip

366

2.62

4.36

7.1

3.4

estimate

0.0

0.00

(3027315) Oxygen [Partial pressure] in Blood

7.57

4.28

5.3

4.2

kpa

8.3

8.5

—

(3018677) aPTT in Platelet poor plasma by Coagulation assay

102

2.87

4.21

2.0

1.7

29.7

29.2

0.19

(3018418) pH of Serum or Plasma

198

2.51

4.11

6.0

3.7

7.4

1.55

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

7.03

4.10

6.9

2.4

61.0

60.9

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

4.06

4.08

3.2

8.7

mmol/l

24.0

25.4

0.74

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.90

3.92

2.1

1.6

—

(40768804) Tissue Pathology biopsy report

277

2.40

3.90

2.5

1.9

—

(3032699) Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection

12.74

3.82

1.3

2.0

—

(3026008) Bacteria identified in Urine by Culture

221

2.39

3.77

3.7

3.1

—

(3009261) Glucose [Presence] in Urine by Test strip

372

2.42

3.76

7.2

3.4

estimate

0.0

0.00

(3021601) Nitrite [Presence] in Urine by Test strip

365

2.38

3.66

9.7

4.6

estimate

0.0

0.00

(40760888) Immunoglobulin light chains.free panel - Serum

8.33

3.63

2.3

3.0

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.92

3.61

2.7

1.5

—

(3013290) Carbon dioxide [Partial pressure] in Blood

6.65

3.59

4.8

4.2

kpa

4.7

4.8

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

118

2.57

3.54

1.5

1.2

iu/ml

44.3

49.5

—

(3029937) Albumin [Presence] in Urine by Test strip

218

2.32

3.52

7.1

3.5

estimate

0.0

0.00

(3030905) Polymorphonuclear cells [#/volume] in Blood

6.17

3.42

6.1

2.4

e9/l

4.6

4.7

—

(3015736) pH of Urine

282

2.23

3.34

6.2

3.0

—

(3042936) Bacteria identified in Isolate by Culture

101

2.58

3.28

2.4

2.5

—

(3044290) Cell count panel - Cerebral spinal fluid

6.81

3.25

1.0

1.1

—

(3045424) Erythrocytes [Presence] in Urine

6.23

3.08

1.9

1.3

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

6.23

3.08

1.7

1.8

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

111

2.46

3.08

1.4

1.2

u/ml

41.8

25.4

—

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

3.15

3.07

3.5

2.9

ng/l

72.9

66.4

0.12

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.61

3.04

2.2

1.5

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

310

2.12

2.96

4.1

2.3

ug/l

322.8

110.0

0.63

285

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

5.75

2.93

1.7

1.6

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

5.33

2.79

2.4

1.8

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

8.74

2.78

2.0

1.7

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

4.06

2.76

1.4

2.5

ug/l

283.2

452.6

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

6.35

2.74

1.0

1.2

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

118

2.29

2.67

2.2

1.9

—

(3013512) EKG study

205

2.08

2.65

6.7

3.8

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

7.49

2.58

2.0

1.6

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

7.49

2.58

4.2

1.3

33.4

31.0

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.82

2.58

2.5

1.6

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

2.50

2.58

4.7

3.4

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

4.66

2.53

1.6

1.3

—

(3021901) Oxygen saturation in Capillary blood

5.28

2.44

2.0

3.1

—

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

6.54

2.40

1.4

1.0

—

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

6.54

2.40

1.2

1.5

—

(3045414) Leukocytes [Presence] in Urine

3.10

2.39

1.7

1.4

—

(3034770) Mitochondria Ab [Titer] in Serum

4.13

2.30

1.1

1.5

—

(4035726)

2.54

2.29

1.4

1.2

—

(40761535) Cells panel - Urine sediment

2.60

2.25

5.6

3.2

—

(43055361) Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count

5.81

2.24

2.4

4.7

—

(3019225) pH of Specimen

2.50

2.21

5.7

4.6

—

(3000492) Spirometry study

2.78

2.19

2.1

1.4

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

4.52

2.19

1.3

1.5

—

(40761536) Microorganisms panel - Urine sediment

2.46

2.14

7.5

3.6

—

(4010399)

2.62

2.13

1.8

1.5

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

5.23

2.10

2.2

2.9

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

5.23

2.10

2.8

3.3

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

4.21

2.07

1.5

1.4

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

4.21

2.07

1.5

1.4

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

3.28

2.07

1.1

1.0

—

(40768443) Skin Pathology biopsy report

3.16

1.99

1.3

1.1

—

(3023419) Bacteria identified in Sputum by Culture

4.75

1.97

1.2

3.8

—

(40758558) Short blood count panel - Blood

173

1.91

1.96

14.7

7.3

—

(3000494) Fungus identified in Specimen by Culture

2.19

1.96

1.6

—

(3022145) Colonoscopy Study observation

2.13

1.86

1.2

1.3

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

4.35

1.85

1.0

2.0

—

(3003327) Ova and parasites identified in Stool by Light microscopy

2.93

1.84

1.6

1.3

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

160

1.89

1.83

6.3

3.3

—

(3019060) Gas panel - Arterial blood

2.33

1.82

5.2

12.1

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

145

1.90

1.78

2.4

2.5

—

(3009508) Creatinine [Moles/volume] in Urine

204

1.81

1.77

6.4

3.0

mmol/l

6.5

7.8

1.07

168

(3022217) INR in Platelet poor plasma by Coagulation assay

2.23

1.76

23.1

23.8

—

1.2

—

(3041096) Erythrocytes [Presence] in Urine by Automated

215

1.77

1.70

7.0

3.1

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

334

1.72

1.68

5.6

4.5

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

108

1.97

1.67

7.2

2.6

e6/l

3.5

3.7

0.03

(3028286) Albumin [Mass/volume] in Serum or Plasma by Electrophoresis

3.14

1.61

1.0

g/l

35.8

38.2

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

3.14

1.61

1.2

1.3

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

2.44

1.60

1.4

1.3

—

(3012516) Albumin [Mass/volume] in Urine

185

1.76

1.56

6.6

3.2

mg/l

23.4

77.9

1.65

120

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

274

1.69

1.55

2.1

1.8

pmol/l

99.5

95.6

0.22

132

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

3.47

1.54

1.8

1.6

—

(3000991) Gas panel - Venous blood

2.33

1.46

3.1

11.6

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

296

1.65

1.46

7.7

3.5

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.98

1.42

9.3

7.5

—

(3044640) Blood type and Crossmatch panel - Blood

217

1.67

1.38

2.6

2.4

—

(3020682) Albumin/Creatinine [Ratio] in Urine

200

1.68

1.37

9.1

4.0

mg/mmol

3.9

11.0

1.48

123

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.49

1.33

1.5

1.6

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

2.61

1.33

2.5

2.0

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

2.61

1.33

2.8

2.2

—

(3002256) Pathology report gross observation

1.92

1.26

1.2

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

2.59

1.16

1.6

2.4

g/l

132.6

132.1

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

156

1.64

1.14

1.2

1.3

u/ml

0.6

0.8

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

115

1.71

1.10

7.3

2.4

e6/l

0.5

1.1

0.70

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

640

1.73

1.09

5.3

4.7

mu/l

2.0

1.9

0.19

577

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

652

1.74

1.08

32.5

13.4

ml/min/173m2

82.2

81.1

0.14

519

(40761511) CBC panel - Blood by Automated count

734

1.83

0.93

30.4

13.0

—

(3012544) pH of Venous blood

1.76

0.83

3.7

2.9

—

(3020891) Body temperature

1.88

0.80

2.8

4.7

—

(3002032) Base excess in Venous blood by calculation

1.72

0.72

3.7

2.5

mmol/l

2.7

2.0

—

(3044889) 12 lead EKG panel

482

1.38

0.70

5.7

3.7

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

447

1.34

0.62

4.5

3.1

u/l

69.0

49.6

0.87

421

(4034850)

0.00

0.61

0.0

10.8

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

197

1.38

0.60

4.8

ug/l

2.5

1.9

0.53

175

(1761868) Lipid panel - Serum or Plasma

256

0.72

0.59

3.6

2.9

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

439

1.33

0.59

4.1

3.1

—

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

1.62

0.55

3.2

2.4

—

(40768797) Stomach Pathology biopsy report

1.49

0.54

1.3

1.2

—

(3025941) Bacteria identified in Stool by Culture

1.53

0.49

1.3

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.49

0.48

2.9

2.3

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

656

1.34

0.45

4.4

4.0

mmol/l

1.4

1.3

0.99

597

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.41

0.0

1.5

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.41

0.0

1.5

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.41

0.0

1.5

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.41

0.0

1.5

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.41

0.0

1.8

—

(3017044) Thyrotropin receptor Ab [Units/volume] in Serum

0.00

0.40

0.0

1.6

—

6.1

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.40

0.0

1.2

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

1.45

0.40

8.6

24.9

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.37

0.34

3.6

2.6

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

1.33

0.34

5.0

2.2

ng/l

667.5

154.0

—

(36660697) Celiac disease serology panel - Serum

1.30

0.31

1.0

1.2

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

678

1.26

0.29

4.6

4.4

mmol/l

1.5

0.41

618

(3022621) pH of Urine by Test strip

1.34

0.29

1.4

2.5

—

(3009542) Hematocrit [Volume Fraction] of Blood

616

1.22

0.28

31.0

14.5

37.5

39.5

0.60

451

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

155

1.20

0.22

3.6

4.2

20.3

21.4

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.21

0.0

5.7

—

174.5

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

3.5

—

18.6

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.21

0.0

1.5

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.5

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.20

0.0

1.8

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

129

1.20

0.18

1.6

1.5

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

698

1.18

0.17

4.9

mmol/l

2.6

2.7

0.76

639

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.72

0.17

1.8

1.5

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

118

0.83

0.15

1.2

1.5

—

(3035941) MCH [Entitic mass]

774

1.22

0.14

54.0

20.5

30.1

30.3

0.38

762

(3024731) MCV [Entitic volume]

774

1.22

0.14

54.0

20.5

91.7

91.2

0.44

762

(3000963) Hemoglobin [Mass/volume] in Blood

775

1.21

0.14

54.6

20.6

g/l

129.4

134.2

2.88

763

(3007461) Platelets [#/volume] in Blood

772

1.25

0.14

54.4

20.6

e9/l

263.7

252.8

0.60

753

(3004119) Hemoglobin [Mass/volume] in Venous blood

1.14

0.10

4.2

2.8

g/l

128.2

123.6

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

684

1.04

0.00

5.9

4.5

mmol/l

5.8

5.9

0.23

618

(3003694) ABO and Rh group [Type] in Blood

201

0.99

0.00

2.1

1.4

—

(4281824)

0.00

0.0

1.0

—

(3047826) Mullerian inhibiting substance [Mass/volume] in Serum or Plasma

0.00

0.0

1.2

—

3.9

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.1

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

0.0

1.0

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.0

2.4

—

(3035933) Granulocytes/100 leukocytes in Blood

0.00

0.0

1.0

—

(3014326) Insulin-like growth factor-I [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

25.1

—

(3036535) Thyroglobulin [Mass/volume] in Serum or Plasma

0.00

0.0

6.0

—

(21494434) Karyotype in Bone marrow

0.00

0.0

1.0

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

0.0

1.1

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.2

—

(3005082) Progesterone [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

31.7

—

(3041145) Herpes simplex virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.0

—

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

0.00

0.0

1.6

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.92

0.00

2.2

1.8

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.90

0.00

1.0

1.9

—

(3051611) Lipemic interference index of Serum or Plasma

0.00

0.0

3.9

—

(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid

0.00

0.0

1.1

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3010838) Calcium [Moles/time] in 24 hour Urine

0.00

0.0

1.4

—

(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

0.00

0.0

1.8

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.0

1.4

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint M13_POYARTOTH and mortality.

Females

Parameter	HR [95% CI]	p-value
M13_POYARTOTH	2.789 [2.0, 3.89]	< 0.001
Birth year	0.993 [0.98, 1.0]	0.129

During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 272 females with M13_POYARTOTH died.

Males

Parameter	HR [95% CI]	p-value
M13_POYARTOTH	2.272 [1.53, 3.36]	< 0.001
Birth year	0.986 [0.97, 1.0]	0.026

During the follow-up period (1.1.1998 — 31.12.2019), 72 out of 194 males with M13_POYARTOTH died.

Mortality risk

Mortality risk for people of age

years, who have M13_POYARTOTH.

N-year risk	Females	Males
1	0.244%	0.365%
5	1.567%	2.344%
10	4.319%	5.549%
15	7.846%	11.556%
20	13.131%	19.031%

Relationships between endpoints

↥

Index endpoint: M13_POYARTOTH – Other conditions related to polyarteritis nodosa

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Other conditions related to polyarteritis nodosa

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints